15 sept. 2026•3 min de lecture
Korean Pharma Secures Minimal Buffer Amid Drug Price Cut Reassessment
The Korean pharmaceutical and biotech sector has secured a limited buffer period as the government delays and adjusts price‑cut criteria for re‑evaluated listed drugs.